{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"3"}]}],"title":"Progressive Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"9"}]}],"title":"Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"}]}],"title":"Expired"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"description":"This measure is the number of subjects (systemic disease only) for each grade of response. Efficacy will be measured in heart, liver, or kidney.\n\nHeart N-terminal (NT)-proBNP response \\>30% and \\> 300 ng/L decrease in patients with baseline NT-proBNP ≥650 ng/L (Patients with progressively worsening renal function cannot be scored for NT-proBNP progression).\n\nImprovement by 2 New York Heart Association (NYHA) classes without an increase in diuretic use or in echocardiographic wall thickness ≥ 2 mm reduction in the interventricular septal thickness by echocardiogram or improvement of ejection fraction by ≥20%.\n\nLiver\n\n≥50% decrease in an initially elevated alkaline phosphatase level, or Decrease in liver size by at least 2 cm by ultrasound.\n\nKidney 50% reduction in 24-hour urine protein excretion (at least 0.5 g/day) without worsening of creatinine or creatinine clearance by 25% over baseline.\n\nSoft Tissue RECIST criteria will be used.","groups":[{"description":"Doxycycline will be administered at dose of 100mg orally twice daily for 1 year.\n\nDoxycycline: Doxycycline will be continued until one of the following criteria is met:\n\n* Patient has completed 1 year of doxycycline therapy\n* Patient develops any grade 3-4 toxicity related to doxycycline use.","id":"OG000","title":"Doxycycline (6 Months)"},{"description":"Doxycycline will be administered at dose of 100mg orally twice daily for 1 year.\n\nDoxycycline: Doxycycline will be continued until one of the following criteria is met:\n\n* Patient has completed 1 year of doxycycline therapy\n* Patient develops any grade 3-4 toxicity related to doxycycline use.","id":"OG001","title":"Doxycycline (1 Year)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"6 months and 1 year","title":"Amyloid Organ Response","type":"SECONDARY","unitOfMeasure":"Participants"}